|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ѫ���� |
|
Ƥ������ |
| ��������������� | |
|
�ƽ������� |
|
����Ӣ��У |
|
��ǧ����У |
| PubMed | |
|
Article by �ƽ������� |
|
Article by ����Ӣ��У |
|
Article by ��ǧ����У |
5-��ɫ����Ƥ������ϵ���о���չ
1. ������������������ҽԺƤ����;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
����5-��ɫ����Ƥ������,��Ҫ��5-��ɫ������������һЩ�����Ƥ�������е������Լ�5-��ɫ����Ƥ��Ѫ�ܡ�����ϸ���з��ӵĵ�������;���������黯����ѹҺ��ɫ���ȶԽ�ʾһЩƤ������5-��ɫ���Ĺ�ϵ����Ҫ�������������˱�Ӧ�ԽӴ���Ƥ�ס���������Ҷ����5-��ɫ�������û��ơ�̽��5-��ɫ����Ƥ�����е����÷�ʽ��;���Լ�����5-��ɫ������ҩ
1. ������������������ҽԺƤ����;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
1. ������������������ҽԺƤ����;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
[2] Balaskas EV,Bamihas GI,Karamouzis M,et al.Histamine and serotonin in uremicc pruritus:effect of ondansetron in CAPD-pruritic patients.Nephron,1998,78(4):395-402.
[3] Kvriakides K,Hussain SK,Hobbs GJ.Management of opioid-induced pruritus:a role for 5-HT3 antagonists? Br J Anaesth,1999,82(3):439-441.
[4] Weiss haar E,Ziethen B,Rohhl FW,et al.The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion:an experimental study.Exp Dermatol,1999,8(4):254-260.
[5] Zylicz Z,Smits C,Krajnik M.Paroxetine for pruritus in advanced cancer.J Pain Symptom Manage,1998,16(2):121-124.
[6] Zalsman G,Sever J,Munitz H.Hair loss associated with paroxetine treatment:a case report.Clin Neuropharmacol,1999,22(4):246-247.
[7] Yamaguchi T,Nagasawa T,Satoh M,et al.Iteh-associated response induced by intradermal serotonin through 5-HT2 receptors in mice.Neurosci Res,1999,35(2):77-83.
[8] Bailey SR,Elliott J.Plasma 5-hydroxytyptamune constricts equine digital blood vessels in vitro:implications for pathogenesis of acute laminitis.Equine Vet J,1998,30(2):124-130.
[9] Bailey SR,Elliott J.The role of prostanoicds and nitric oxide in endotoxininduced hyporesponsiveneas of equine digital blood vessels.Equine Vet J,1999,31(3):212-218.
[10] Laemmel E,Stucker O,Darmon PL,et al.Characterization of the specific response to serotonin of mouse tumor-feeding arterioles.lnt J Radiat Biol,1998,74(3):379-386.
[11] Luncleberg L,Liang Y,Sundstrom E,et al.Serotonin in human allergic contact dermatitis.An immunohistochemical and high-performce liquid chromatographic study.Arch Dermatol Res,1999,291(5):269-274.
[12] Askenase PW,Kawikova I,Paliwal V,et al.A new paradigm of T cell allergy:requirement for the B-1 cell subset.Int Arch Allergy Immmunol,1999,118(2-4):145-149.
[13] Lundeberg L,Mutt V,Nordlind K.Inhibitory effect of vasoactive intestinal peptide on the challenge poase of allergic contact dermatitis in humans.Acta Derm Venereol,1999,79(3):178-182.
[14] Richard MA,Serres F,Giravalli P,et al.Plasma tryptophan bioavailability during chronic urtncaria.Ann Dermatol Venereol,1998,125(3):167-170.
[15] Stein DT,Mendelsohn I,Potoenik F,et al.Use of the selective serotonin reuptake inhibitor citalopram in a poasible animal analogue of obsessivecompulsive disorder.Depress Anxiety,1998,8(1):39-42.
[16] Iyengar B.The UV-responsive melanocyte system:a peripheral network for photoperiodic time measurements.A function of indol eamine expression.Acta Anat (Basel),1998,163(4):173-178.
[17] Iyengar B.Photomodulation of the melanocyte cell cycle by indoleamines.Biol Signals Recept,1998,7(6):345-350.